Search

Displaying results 2291 - 2300 of 10000 in total
  1. Drug

    Tradipitant

    go.drugbank.com/drugs/DB12580
    ApprovedInvestigational

    [A275353] Approved by the FDA on December 30, 2025, tradipitant is indicated for the prevention of vomiting induced by motion. … [L54903] Tradipitant has also been investigated in gastroparesis,COVID-19-induced pneumonia, and atopic dermatitis.[A275348, A275358, A275363]

  2. Drug

    Daclatasvir

    go.drugbank.com/drugs/DB09102
    ApprovedInvestigationalWithdrawn

    The same dosing regimen can be used as first-line therapy in patients with genotype 3 without cirrhosis and second-line therapy in genotype 3 patients with compensated cirrhosis. … The most common critical NS5A amino acid substitutions that led to reduced susceptibility to daclatasvir therapy occured at position Q30 (Q30H/K/R) and M28 in genotype 1a patients and Y93H in genotype

  3. Drug

    Abciximab

    go.drugbank.com/drugs/DB00054
    ApprovedWithdrawn

    It also binds to vitronectin (αvβ3) receptor found on platelets and vessel wall endothelial and smooth muscle cells.

  4. Drug

    Dydrogesterone

    go.drugbank.com/drugs/DB00378
    ApprovedInvestigationalWithdrawn

    Unlike many other progestational compounds, dydrogesterone produces no increase in temperature and does not inhibit ovulation.

  5. Drug

    Carbocisteine

    go.drugbank.com/drugs/DB04339
    ApprovedInvestigational

    reported by physicians in France and Italy. … [A230993] Carbocisteine is currently not FDA or Health Canada approved, but is approved for use in Asia, Europe, and South America.

    Products: MADECASOL N
  6. Drug

    Bosutinib

    go.drugbank.com/drugs/DB06616
    ApprovedInvestigational

    ABL ratio on an international scale, with bosutinib treatment. … [A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving

  7. Drug

    Ripasudil

    go.drugbank.com/drugs/DB13165
    Investigational

    It was first approved for treatment in Japan in September 2014. This medication is available in the form of a 0.4% eye drop solution under the brand name Glanatec.

    Categories: Sympathomimetics in Glaucoma Therapy
  8. Drug

    Emapalumab

    go.drugbank.com/drugs/DB14724
    ApprovedInvestigational

    Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018.

  9. Drug

    Glycerol phenylbutyrate

    go.drugbank.com/drugs/DB08909
    ApprovedInvestigational

    Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.

  10. Drug

    Icosapent

    go.drugbank.com/drugs/DB00159
    ApprovedInvestigationalNutraceutical

    Important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. … A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardiovascular disorders, prevents platelet aggregation, and inhibits arachidonic acid conversion into the thromboxane

    Mixtures: Live-well™ Toco-E Capsule, Virt-PN Plus